Remove Eating disorders Remove Genetics and mental health Remove Pharmaceuticals
article thumbnail

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

SHOW MORE NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD. Sanom/Adobestock BREAKING NEWS A new formulation of ketamine is progressing through a novel US Food and Drug Administration review pathway, announced NRx Pharmaceuticals.

article thumbnail

The Psychiatric Pipeline in Review: Quarter 2, 2025

Psychiatric Times

The top 4 disease states this quarter were schizophrenia (41.7%), major depressive disorder (25%), and treatment-resistant depression (16.7%), and suicidal depression (16.7%). MM120 ODT is a proprietary, pharmaceutically optimized form of lysergic acid diethylamide (LSD).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Branding Diseases—How Drug Companies Market Psychiatric Conditions: An Interview with Ray Moynihan

Mad in America

R ay Moynihan is an accomplished health journalist and author who has won several awards for his work. He is known for his use of sharp humor, which can be seen in his mock documentary about a fictional illness called ‘Motivational Deficiency Disorder.’ This applies in the mental illness world and everywhere in medicine.

article thumbnail

“All Real Living Is Meeting”: Brent Robbins on Love, Death, and the Possibilities of Psychology

Mad in America

His work spans everything from the cultural history of mental illness to mindfulness, death anxiety, and resiliencenot the hollow kind that comes from pretending everythings fine, but the kind that comes from staring into the void and refusing to flinch. On a personal note, Brent has played a foundational role in my own journey.